Blog

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…

CertaraAugust 6, 2025

On-Demand Webinar

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…

CertaraAugust 5, 2025

On-Demand Webinar

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

CertaraJuly 29, 2025

Press Coverage

The Medicine Maker: The Biosimulation Generation

The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…

Danielle PillsburyJuly 1, 2025

Publication

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…

CertaraJune 19, 2025

On-Demand Webinar

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…

CertaraJune 18, 2025

Blog

What are the most common in vitro drug-drug interaction study gaps?

Certara drug interaction science experts share data and experimental design gaps commonly found in in…

CertaraJune 9, 2025

Publication

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…

CertaraJune 8, 2025

On-Demand Webinar

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…

CertaraMay 5, 2025

Video

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

JTNDc2NyaXB0JTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZmYXN0Lndpc3RpYS5jb20lMkZwbGF5ZXIuanMlMjIlMjBhc3luYyUzRSUzQyUyRnNjcmlwdCUzRSUzQ3NjcmlwdCUyMHNyYyUzRCUyMmh0dHBzJTNBJTJGJTJGZmFzdC53aXN0aWEuY29tJTJGZW1iZWQlMkZvZTJ5enJvYmx3LmpzJTIyJTIwYXN5bmMlMjB0eXBlJTNEJTIybW9kdWxlJTIyJTNFJTNDJTJGc2NyaXB0JTNFJTNDc3R5bGUlM0V3aXN0aWEtcGxheWVyJTVCbWVkaWEtaWQlM0QlMjdvZTJ5enJvYmx3JTI3JTVEJTNBbm90JTI4JTNBZGVmaW5lZCUyOSUyMCU3QiUyMGJhY2tncm91bmQlM0ElMjBjZW50ZXIlMjAlMkYlMjBjb250YWluJTIwbm8tcmVwZWF0JTIwdXJsJTI4JTI3aHR0cHMlM0ElMkYlMkZmYXN0Lndpc3RpYS5jb20lMkZlbWJlZCUyRm1lZGlhcyUyRm9lMnl6cm9ibHclMkZzd2F0Y2glMjclMjklM0IlMjBkaXNwbGF5JTNBJTIwYmxvY2slM0IlMjBmaWx0ZXIlM0ElMjBibHVyJTI4NXB4JTI5JTNCJTIwcGFkZGluZy10b3AlM0ExMDAuMCUyNSUzQiUyMCU3RCUzQyUyRnN0eWxlJTNFJTIwJTNDd2lzdGlhLXBsYXllciUyMG1lZGlhLWlkJTNEJTIyb2UyeXpyb2JsdyUyMiUyMGFzcGVjdCUzRCUyMjEuMCUyMiUzRSUzQyUyRndpc3RpYS1wbGF5ZXIlM0U=

CertaraMarch 27, 2025

Drug Safety

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Insights Without Animals: Leveraging Human-on-a-Chip & PBPK Modeling

The Medicine Maker: The Biosimulation Generation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

What are the most common in vitro drug-drug interaction study gaps?

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Newsletter sign up

Quick links

Solutions

Contact